Loading the evidence…
Follow an intervention from preclinical studies to human trials and reported outcomes.
| THERAPY / MECHANISM | INJURY MODELS | STUDIES | REPORTED OUTCOME | Open record |
|---|---|---|---|---|
| Veliparib (PARP-1 inhibitor); complemented by PARP-1 genetic deletion PARP 1, 2 and 3 inhibitor (INHIBITOR, direct interaction, disease efficacy true; mec_id 5662) | TBI | 12016 | Not approved | |
| VX-765 (belnacasan) Caspase-1 inhibitor (INHIBITOR, direct interaction); prodrug | Spinal cord injury · TBI | 22018–2020 | Not approved | |
| Xenon ChEMBL records list diagnostic-agent and MRI contrast-agent mechanisms for xenon isotopes; ATC N01AX15 classifies xenon as a general anaesthetic. | Ischaemia-reperfusion · TBI | 32015–2020 | No trauma translation |
Study counts are reported at therapy level and can differ from the number of itemised publications. Outcomes are research classifications, not treatment recommendations.